Oncology – Gastrointestinal
Comprehensive imaging characterization of colorectal liver metastases.
13 Feb, 2022 | 21:27h | UTCComprehensive Imaging Characterization of Colorectal Liver Metastases – Frontiers in Oncology
Review: Immunotherapies for hepatocellular carcinoma.
11 Feb, 2022 | 08:11h | UTCImmunotherapies for hepatocellular carcinoma – Cancer Medicine
M-A: Neoadjuvant therapy vs. direct to surgery for T4 colon cancer.
9 Feb, 2022 | 08:28h | UTCNeoadjuvant therapy versus direct to surgery for T4 colon cancer: meta-analysis – British Journal of Surgery (link to abstract – $ for full-text)
Expert opinion on management of pancreatic exocrine insufficiency in pancreatic cancer.
8 Feb, 2022 | 08:31h | UTCExpert opinion on management of pancreatic exocrine insufficiency in pancreatic cancer – ESMO Open
RCT: In patients with advanced esophageal squamous-cell carcinoma, both nivolumab plus chemotherapy and nivolumab plus ipilimumab resulted in longer overall survival than chemotherapy alone.
3 Feb, 2022 | 09:46h | UTCNivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary (2021 ASCO Annual Meeting): Nivolumab Plus Chemotherapy and Nivolumab Plus Ipilimumab as First-Line Treatment for Patients With Advanced Esophageal Cancer – The ASCO Post
Commentary on Twitter
First-line treatment of advanced esophageal squamous-cell carcinoma with either nivolumab plus chemo or nivolumab plus ipilimumab resulted in a significant overall survival benefit and durable responses as compared with chemo alone. https://t.co/a000bDsh1N pic.twitter.com/NuY2eX58gp
— NEJM (@NEJM) February 2, 2022
M-A: Laparoscopic versus open distal gastrectomy for gastric cancer.
3 Feb, 2022 | 08:30h | UTC
Review: Primary and metastatic peritoneal surface malignancies.
2 Feb, 2022 | 08:33h | UTCPrimary and metastatic peritoneal surface malignancies – Nature Reviews Disease Primers (if the link is paywalled, try this one)
Infographic: Primary and metastatic peritoneal surface malignancies – Nature Reviews Disease Primers (if the link is paywalled, try this one)
Commentary on Twitter
Treatment modalities for #peritoneal surface malignancies can be combined or used sequentially according to underlying #tumour type, disease extent and patients' condition and preference.https://t.co/cIkVAJRSaj pic.twitter.com/PUP1BtoTxE
— Nature Reviews Disease Primers (@DiseasePrimers) December 21, 2021
M-A: Clinical and endoscopic characteristics associated with post-endoscopy upper gastrointestinal cancers.
28 Jan, 2022 | 08:08h | UTCClinical and Endoscopic Characteristics Associated with Post-Endoscopy Upper Gastrointestinal Cancers: a Systematic Review and Meta-analysis – Gastroenterology (link to abstract – $ for full-text)
Long-Term Results of RCT: Neoadjuvant chemoradiotherapy vs. upfront surgery for resectable and borderline resectable pancreatic cancer.
28 Jan, 2022 | 08:01h | UTCNeoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
Review: Genotypic and phenotypic characteristics of hereditary colorectal cancer.
26 Jan, 2022 | 01:16h | UTCGenotypic and Phenotypic Characteristics of Hereditary Colorectal Cancer – Annals of Coloproctology
Review: Treatment for peritoneal metastasis of patients with colorectal cancer.
26 Jan, 2022 | 01:17h | UTCTreatment for Peritoneal Metastasis of Patients With Colorectal Cancer – Annals of Coloproctology
RCT: The addition of trastuzumab to neoadjuvant chemoradiotherapy for HER2-overexpressing esophageal cancer did not improve outcomes.
24 Jan, 2022 | 08:04h | UTCTrastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
In a phase III trial in 203 pts with HER2+ oesophageal cancer, adding trastuzumab to neoadjuvant CRT did not significantly improve mDFS (19.6 vs 14.2 months; HR 0.99; P = 0.97). The incidence of grade 3 and 4 TRAEs was 43% & 21% vs 54% & 22%: https://t.co/wx0NmVMyCR #esocsm
— NatureRevClinOncol (@NatRevClinOncol) January 21, 2022
ASTRO issues clinical guideline on external-beam radiation therapy for primary liver cancers.
19 Jan, 2022 | 08:36h | UTCOriginal Article: External Beam Radiation Therapy for Primary Liver Cancers: An ASTRO Clinical Practice Guideline – Practical Radiation Oncology
M-A: Role of adjuvant therapy in esophageal cancer patients after neoadjuvant therapy and esophagectomy.
19 Jan, 2022 | 08:19h | UTCRole of Adjuvant Therapy in Esophageal Cancer Patients After Neoadjuvant Therapy and Esophagectomy: A Systematic Review and Meta-analysis – Annals of Surgery (link to abstract – $ for full-text)
Commentary on Twitter
New in Annals! Meta-analysis examines the effect of adjuvant therapy on overall survival after esophagectomy
Free download – https://t.co/r2SY34ZiVE
Lee, Samarasinghe, @michaelhylee, @luxmy_thiru, @ShargallYaron, Finley, @wc_hanna, Levine, Juergens, Agzarian pic.twitter.com/UV4v6leCcr
— Annals of Surgery (@AnnalsofSurgery) November 2, 2021
RCT: Nivolumab plus chemotherapy improved progression-free survival, but not overall survival, compared to placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer.
16 Jan, 2022 | 22:38h | UTCNivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Preliminary findings from a randomized trial showed promising results from dual PD-1 and HER2 blockade in HER2-positive gastric cancer.
14 Jan, 2022 | 08:03h | UTCThe KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer – Nature
Commentary on Twitter
Nature research paper: Combining immunotherapy with chemotherapy and targeted agents has the potential to improve the outcome of patients with advanced HER2-positive gastric tumours https://t.co/CNAgZObuTS pic.twitter.com/FWGwQzf4ze
— nature (@Nature) December 15, 2021
ASCO Guideline Update: Adjuvant Therapy for Stage II Colon Cancer.
13 Jan, 2022 | 08:19h | UTCAdjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update – Journal of Clinical Oncology
Meta-analysis (mostly of observational studies): In patients undergoing pancreaticoduodenectomy, routine nasogastric decompression is associated with increased rates of delayed gastric emptying, major complications, and longer length of stay compared to no routine nasogastric decompression.
8 Jan, 2022 | 22:44h | UTCRelated Study: Nasogastric Decompression vs No Decompression After Pancreaticoduodenectomy: The Randomized Clinical IPOD Trial – JAMA Surgery
Commentary on Twitter
Nasogastric decompression after pancreaticoduodenectomy ? what is your practice?!
? Routine NG tube associated with ⬆️ rates of DGE, major complications and longer length of stay
✅ @ErasSociety policies should be standard
New meta analys on @BjsOpen https://t.co/OStyWOfrPV pic.twitter.com/tuwjPYFWia
— Giovanni Marchegiani (@Gio_Marchegiani) January 3, 2022
Review: Immunotherapies for hepatocellular carcinoma.
14 Dec, 2021 | 08:47h | UTCImmunotherapies for hepatocellular carcinoma – Nature Reviews Clinical Oncology (free for a limited period – if the link is paywalled, try this one)
Colorectal cancer incidence, mortality, tumor characteristics, and treatment before and after the introduction of the fecal immunochemical testing-based screening program in the Netherlands: a population-based study.
13 Dec, 2021 | 08:50h | UTCColorectal cancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the faecal immunochemical testing-based screening programme in the Netherlands: a population-based study – The Lancet Gastroenterology & Hepatology (link to abstract – $ for full-text)
Commentary on Twitter
New research – Breekveldt et al – #Colorectalcancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the FIT-based #screening programme in the #Netherlands: a population-based studyhttps://t.co/nW9SVAhRxE#GITwitter #crcsm pic.twitter.com/GGRF9Az0tg
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) November 23, 2021
M-A: Efficacy and safety associated with immune checkpoint inhibitors in unresectable hepatocellular carcinoma.
8 Dec, 2021 | 09:48h | UTC
Commentary on Twitter
This meta-analysis of RCTs shows immune checkpoint inhibitors are associated with demonstrated the superior efficacy and safety of versus standard systemic therapies in patients with unresectable hepatocellular carcinoma. https://t.co/fJdFng69qH
— JAMA Network Open (@JAMANetworkOpen) December 6, 2021
RCT: Cytoreductive surgery for relapsed ovarian cancer.
2 Dec, 2021 | 09:51h | UTC
Review: Current treatment and future directions in the management of anal cancer.
1 Dec, 2021 | 08:38h | UTC
M-A (mostly observational studies): Comparison of gastrojejunostomy to endoscopic stenting for gastric outlet obstruction.
30 Nov, 2021 | 10:08h | UTC
M-A: Treatment for gastrointestinal and pancreatic neuroendocrine tumors.
26 Nov, 2021 | 09:53h | UTCSummary: Treatment options for neuroendocrine tumours – Cochrane Library